Immune suppressor mechanisms in patients with GI cancer
$155,811ZIAFY2025CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications, trials & patents
Paper 38205877Paper 38184304Paper 36754451Paper 35366023Paper 35331674Paper 34340996Paper 33508529Paper 33235387Paper 32060001Paper 31996388Paper 31912614Paper 29909986Paper 29427558Paper 29066575Paper 28857485Paper 27816492Paper 24201974Paper 23243621Paper 23108303Paper 23011590Paper 22615204Paper 22304731Paper 21493801Paper 21237299
Abstract
We treated patients with cholangiocarcinoma using the combination of a-VEGF/a-CTLA4/a-PD-L1. We obtained PBMC< blood, and tumor biopsies and performed immune analysis using these samples in parallel to murine studies. We observed that treatment led to a BAFF- and interleukin (IL)-12-dependent expansion and rewiring of T regulatory cells (Tregs) toward an anti-tumor T helper-1 (Th-1)-like fragile state. These findings have important implications of our understanding how a-VEGF treatment, which is initially considered to be an anti-angiogenic therapy,has on anti-tumor immune responses.
View original record on NIH RePORTER →